CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,426,063 | -19.5% | 31,418 | -0.5% | 0.05% | -15.5% |
| Q2 2023 | $1,772,340 | +24.1% | 31,570 | 0.0% | 0.06% | +16.0% |
| Q1 2023 | $1,427,911 | +31.4% | 31,570 | +18.1% | 0.05% | +28.2% |
| Q4 2022 | $1,086,778 | -54.1% | 26,735 | -26.2% | 0.04% | -55.7% |
| Q3 2022 | $2,368,000 | -46.2% | 36,231 | -50.0% | 0.09% | +11.4% |
| Q2 2022 | $4,404,000 | +75.3% | 72,462 | +81.0% | 0.08% | 0.0% |
| Q1 2022 | $2,512,000 | -0.8% | 40,026 | +19.8% | 0.08% | +3.9% |
| Q4 2021 | $2,531,000 | +1.6% | 33,397 | +50.1% | 0.08% | -7.3% |
| Q3 2021 | $2,490,000 | -30.9% | 22,249 | +0.0% | 0.08% | -31.7% |
| Q2 2021 | $3,601,000 | +162.5% | 22,243 | +97.5% | 0.12% | +135.3% |
| Q1 2021 | $1,372,000 | +209.0% | 11,262 | +288.3% | 0.05% | +218.8% |
| Q4 2020 | $444,000 | +82.7% | 2,900 | 0.0% | 0.02% | +45.5% |
| Q3 2020 | $243,000 | +14.1% | 2,900 | 0.0% | 0.01% | +22.2% |
| Q2 2020 | $213,000 | – | 2,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |